[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n NFpStAJh1yCVyyOQd2bTMcFaxJKS46OoeIC8Y1N4Qw7JcVDp3+HYnvyMUp7gHplW\n M9ND6/3kBnOB6K5STAyb8A==\n\n', u'0000351346-04-000067.txt : 20040921\n', u'0000351346-04-000067.hdr.sgml : 20040921\n', u'20040920180806\nACCESSION NUMBER:\t\t0000351346-04-000067\nCONFORMED SUBMISSION TYPE:\t8-K/A\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040917\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nFILED AS OF DATE:\t\t20040921\nDATE AS OF CHANGE:\t\t20040920\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tBIOMET INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000351346\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]\n\t\tIRS NUMBER:\t\t\t\t351418342\n\t\tSTATE OF INCORPORATION:\t\t\tIN\n\t\tFISCAL YEAR END:\t\t\t0531\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K/A\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-15601\n\t\tFILM NUMBER:\t\t041038173\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t56 EAST BELL DR\n\t\tCITY:\t\t\tWARSAW\n\t\tSTATE:\t\t\tIN\n\t\tZIP:\t\t\t46582\n\t\tBUSINESS PHONE:\t\t5742676639\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t56 E BELL DRIVE\n\t\tSTREET 2:\t\tP O BOX 587\n\t\tCITY:\t\t\tWARSAW\n\t\tSTATE:\t\t\tIN\n\t\tZIP:\t\t\t46581-0587\n', u'\n', u'\n', u'8-K/A\n', u'1\n', u'a8k0501.htm\n', u'\n', u'SEC Form 8-K Filed 7/7/2003', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES', u'\n', u'\n', u'\n', u'\n', u'\n', u'SECURITIES AND EXCHANGE COMMISSION', u'\n', u'\n', u'\n', u'\n', u'\n', u'WASHINGTON, DC\xa0 20549', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'FORM 8-K/A', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'CURRENT REPORT', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Date of report (Date of earliest event reported): ', u'September 17, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'BIOMET, INC.', u'\n', u'\n', u'\n', u'\n', u'\n', u'(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Indiana', u'\n', u'\n', u'\n', u'0-12515', u'\n', u'\n', u'\n', u'35-1418342', u'\n', u'\n', u'\n', u'\n', u'\n', u'(State or other jurisdiction of incorporation)', u'\n', u'\n', u'\n', u'\xa0(Commission File Number)\xa0', u'\n', u'\n', u'\n', u'\xa0(IRS Employer Identification No.)\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'56 East Bell Drive', u'\n Warsaw, Indiana 46582', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Address of Principal Executive Offices, including\xa0 Zip Code)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'(574) 267-6639', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Registrant\u2019s Telephone Number, Including Area Code)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Not Applicable', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Former Name or Former Address, if Changed Since Last Report)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the\nregistrant under any of the following provisions:', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\nItem 2.02. Results of Operations and Financial Condition.', u'\n', u'\n', u'On September 21, 2004, Biomet, Inc. issued a press release announcing its corrected earnings for the first quarter ended August\n31, 2004. The Company is reporting these corrected first quarter results to eliminate the tax effect on the purchased in-process\nresearch and development in relation to its Interpore International, Inc. acquisition. In the previous press release dated August\n17, 2004, the Company tax effected the write off of in-process research and development.\xa0 According to EITF 96-7, in-process\nresearch and development is written off prior to the measurement of deferred taxes in a purchase business combination.\xa0 The\neffect of this change is to increase book tax expense for the quarter, which reduces net income by $9,055,000 and reduces goodwill\nrecorded in connection with this transaction for the same amount.\xa0 The "As Adjusted" quarterly results disclosed in the\nprevious press release have not changed.', u'\n', u'\n', u'A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.', u'\n', u'\n', u'The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of\nSection 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section.\xa0 The information in\nthis Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be\nexpressly set forth by specific reference in such filing.', u'\n', u'\n', u'Item 9.01. Financial Statement and Exhibits.', u'\n', u'\n', u"Exhibit 99.1\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Press Release announcing Biomet Inc.'s corrected\nearnings for the first quarter ended August 31, 2004.", u'\n', u'\n', u'\n', u'\n', u'\n', u'SIGNATURES', u'\n', u'Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on\nits behalf by the undersigned hereunto duly authorized.', u'\n', u'BIOMET, INC.', u'\n', u'\n', u'\n', u'\xa0 /s/ Gregory D. Hartman\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n\nBy: Gregory D. Hartman', u'\nIts:\xa0 Senior Vice President - Finance', u'\n\xa0\xa0\xa0\xa0 \xa0 (Principal Financial Officer)', u'\n', u'Date: September 20, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'EX-99\n', u'2\n', u'pr1tsqtr.htm\n', u'\n', u'9/11/00 8:41 AM', u'\n', u'\n', u'\n', u'\n', u'\n', u'Warsaw, IN . . . September 21, 2004 . . . (NASDAQ:BMET)', u'\n', u'\n', u'BIOMET ANNOUNCES RECORD FIRST QUARTER RESULTS, corrected', u'\n', u'\n', u'The Company is reporting these corrected first quarter results to eliminate the tax effect on the\npurchased in-process research and development in relation to its Interpore International, Inc. acquisition. In the previous press\nrelease dated August 17, 2004, the Company tax effected the write off of in-process research and development.\xa0 According to\nEITF 96-7, in-process research and development is written off prior to the measurement of deferred taxes in a purchase business\ncombination.\xa0 The effect of this change is to increase book tax expense for the quarter, which reduces net income by\n$9,055,000 and reduces goodwill recorded in connection with this transaction by the same amount.\xa0 The "As Adjusted" quarterly\nresults disclosed in the previous press release have not changed.', u'\n', u'\n', u"Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by\nmusculoskeletal medical specialists in both surgical and non-surgical therapy.\xa0 The Company's product portfolio encompasses\nreconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive\nimplants; fixation devices, including electrical bone growth stimulators, internal and external orthopedic fixation devices,\ncraniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware\nand orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products.\xa0 Headquartered in\nWarsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.", u'\n', u'\n', u'For further information contact Greg W. Sasso, Vice President, Corporate Development and\nCommunications at (574) 372-1528 or Barb Goslee, Manager, Corporate Communications at (574) 372-1514.', u'\n', u'\n', u"This press release contains certain statements that are \u201cforward-looking statements\u201d\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as\namended.\xa0 Although the Company believes that the assumptions, on which the forward-looking statements contained herein are\nbased, are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence\nor non-occurrence of future events.\xa0 There can be no assurance that the forward-looking statements contained in this press\nrelease will prove to be accurate.\xa0 Some of the factors that could cause actual results to differ from those contained in\nforward-looking statements made in this press release include the success of the Company's principal product lines, the Company's\nability to develop and market new products and technologies in a timely manner, government regulation, currency exchange rate\nfluctuations, reimbursements from third party payors, litigation, and other risk factors as set forth from time to time in the\nCompany's filings with the SEC.\xa0 The inclusion of a forward-looking statement herein should not be regarded as a\nrepresentation by the Company that the Company\u2019s objectives will be achieved.\xa0 The Company undertakes no obligation to\npublicly update forward-looking statements, whether as a results of new information, future events or otherwise.", u'\n', u'\n', u'All of Biomet\u2019s financial information may be obtained on our website at www.biomet.com or you\nmay contact us by e-mail at investor.relations@biometmail.com.', u'\n', u'\n', u'\n', u'BIOMET, INC. - - QUARTERLY RESULTS', u'\n', u'FOR THE QUARTERS ENDED AUGUST 31', u'\n', u'(in thousands, except per share data)', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'Adjustments*', u'\n', u'\n', u'\n', u'As Adjusted*', u'\n', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net Sales', u'\n', u'\n', u'\n', u'$\xa0 438,160', u'\n', u'\n', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'$\xa0 438,160', u'\n', u'\n', u'\n', u'\n', u'$\xa0 370,319', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cost of Sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 125,972', u'\n', u'\n', u'\n', u'\xa0\xa0 (7,002) (a)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 118,970', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 105,618', u'\n', u'\n', u'\n', u'\n', u'\n', u'Gross Profit', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 312,188', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 7,002', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 319,190', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0 264,701', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'S, G, & A', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 160,460', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 160,460', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 132,397', u'\n', u'\n', u'\n', u'\n', u'\n', u'R & D', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 44,496', u'\n', u'\n', u'\n', u'\xa0 (26,020)(b)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 18,476', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 14,748', u'\n', u'\n', u'\n', u'\n', u'\n', u'Operating Income', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 107,232', u'\n', u'\n', u'\n', u'\xa0\xa0 33,022', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 140,254', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 117,556', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other Income (Expense), Net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 (728)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 (728)', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 3,021', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Before Taxes And Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 106,504', u'\n', u'\n', u'\n', u'\xa0\xa0 \xa0 33,022', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 139,526', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 120,577', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Taxes', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 46,071', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 2,432(c)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 48,503', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 41,979', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Before Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 60,433', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 30,590', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 91,023', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 78,598', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 \xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n- -', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 2,120', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net Income', u'\n', u'\n', u'\n', u'\xa0 $\xa0\xa0 60,433', u'\n', u'\n', u'\n', u'$\xa0\xa0 30,590', u'\n', u'\n', u'\n', u'\xa0 $\xa0\xa0\xa0\xa0 91,023', u'\n', u'\n', u'\n', u'\n', u'$\xa0\xa0\xa0\xa0 76,478', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Earnings per Share', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .24', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .12', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .36', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .30', u'\n', u'\n', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .24', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .12', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .36', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .30', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic Shares Outstanding', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 253,856', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 253,856', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 256,847', u'\n', u'\n', u'\n', u'\n', u'\n', u'Diluted Shares Outstanding', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 255,950', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 255,950', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 258,282', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'U.S. sales', u'\n', u'\n', u'\n', u'$\xa0 296,304', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 252,095', u'\n', u'\n', u'\n', u'\n', u'\n', u'Foreign sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 141,856', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 118,224', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Reconstructive sales', u'\n', u'\n', u'\n', u'$\xa0 282,482', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 233,439', u'\n', u'\n', u'\n', u'\n', u'\n', u'Fixation sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 62,713', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 62,133', u'\n', u'\n', u'\n', u'\n', u'\n', u'Spinal products', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 52,909', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 37,967', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other product sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 40,056', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 36,780', u'\n', u'\n', u'\n', u'\n', u'\n', u'(a)\xa0\xa0 Current period impact of inventory step-up related to the acquisition of the\ninterest of Merck KGaA in the Biomet Merck joint venture and Interpore International, Inc.', u'\n', u'(b)\xa0\xa0 In-process research and development written off as of the closing date related to\nthe acquisition of Interpore International, Inc.', u'\n', u'(c)\xa0\xa0 Tax effect of item a above.', u'\n', u'\n', u'*Adjusted results, which are non-GAAP financial measures, exclude acquisition costs, including\ninventory step-up and write off of in-process research and development.\xa0 We have included these adjusted measures to provide\nmanagement and investors with a better understanding of our results, because expenses related to these acquisitions in the current\nquarter and the remainder of fiscal year 2005 are not indicative of our future operating results.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Consolidated Balance Sheets', u'\n', u'\n', u'\n', u'August 31, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'May 31, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'Assets', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Cash and Investments', u'\n', u'\n', u'\n', u'$\xa0 158,618', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 235,612', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Accounts and notes receivable, net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 449,436', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 465,949', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Inventories', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 424,997', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 389,391', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other current assets', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 116,055', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 \xa0\xa0 91,256', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Fixed Assets, net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 283,573', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 268,826', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Goodwill', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 444,124', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 266,860', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other Assets', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 108,042', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 69,803', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0 Total Assets', u'\n', u'\n', u'\n', u'$1,984,845', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$1,787,697', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u"Liabilities and Stockholders' Equity", u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Current Liabilities', u'\n', u'\n', u'\n', u'$\xa0\xa0 537,995', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 313,402', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other Liabilities', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 38,188', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 26,085', u'\n', u'\n', u'\n', u'\n', u'\n', u"\xa0 Stockholders' Equity", u'\n', u'\n', u'\n', u'\xa0 1,408,662\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 1,448,210', u'\n', u'\n', u'\n', u'\n', u'\n', u"\xa0\xa0\xa0 Total Liabilities and Stockholders' Equity", u'\n', u'\n', u'\n', u'$1,984,845', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$1,787,697', u'\n', u'\n', u'\n', u'\n', u'\n', u'The above balance sheet includes the preliminary purchase price allocation in connection with the\nInterpore acquisition.\xa0 The Company believes that changes, if any, when the purchase price allocation is finalized, will not\nbe material.', u'\n', u'\n', u'* * *', u'\n', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']